Abstract
Hepatic metabolism is often a major contributor to drug clearance from the body, highlighting the utility of in vitro liver systems to address chemotypes that undergo extensive metabolism. Drug metabolism can be assessed in a variety of in vitro test systems, including microsomes, cytosol or S9 fractions, hepatocytes (suspension or plated), and isolated liver slices. In drug discovery, metabolic stability is typically determined by measuring the depletion of test compound over time in a relevant in vitro system. Most commonly used in vitro systems are liver microsomes and suspension hepatocytes, which are amenable to automated, high-throughput assay formats. Test compound is quantified in samples using LC/MS/MS, and its metabolic half-life in the in vitro test system is derived from percent remaining vs. time data. Half-life data can be used to rank order compounds according to stability, derive SAR to improve metabolic stability for chemotypes suffering from high turnover, and predict in vivo clearance. The latter is of particular importance to understand in vitro-in vivo correlations and select compounds with appropriate pharmacokinetics in humans. This chapter provides details on the methods used to investigate metabolic stability of test compounds in liver microsomes (for both cytochrome P450s and UDP-glucuronosyltransferases) and in suspension hepatocytes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825–833
Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8(1):E101–E111
Fisher MB et al (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33(3–4):273–297
Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14(6):611–650
Hutzler JM et al (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9(2):153–168
Chauret N, Gauthier A, Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26(1):1–4
Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27(11):1350–1359
Houston JB (1994) Utility of in vitro drug meta-bolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47(9):1469–1479
Lau YY et al (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30(12): 1446–1454
Naritomi Y et al (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31(5): 580–588
Brown HS, Griffin M, Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35(2):293–301
Chao P, Uss AS, Cheng KC (2010) Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 6(2):189–198
Klopf W, Worboys P (2010) Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery. Comb Chem High Throughput Screen 13(2):159–169
Chiba M, Ishii Y, Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11(2):262–276
Walsky RL et al (2012) Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 40(5):1051–1065
Acknowledgements
The views expressed here are solely those of the author and do not reflect the opinions of Janssen Research & Development, LLC.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Coe, K.J., Koudriakova, T. (2014). Metabolic Stability Assessed by Liver Microsomes and Hepatocytes. In: Caldwell, G., Yan, Z. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-742-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-62703-742-6_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-741-9
Online ISBN: 978-1-62703-742-6
eBook Packages: Springer Protocols